Incyte Corp
INCY
查看详细走势图
108.390USD
+5.630+5.48%
收盘 02/06, 16:00（美东）报价延迟15分钟
21.26B总市值
17.97市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.48%
5天
+8.31%
1月
-1.97%
6月
+38.61%
今年开始到现在
+9.74%
1年
+46.22%
查看详细走势图
TradingKey Incyte Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
Incyte Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名13/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价104.31。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Incyte Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Incyte Corp亮点
亮点风险
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
业绩高增长
公司营业收入稳步增长，连续3年增长24.94%
估值低估
公司最新PE估值17.97，处于3年历史低位
机构减仓
最新机构持股206.94M股，环比减少0.42%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值34.29K
分析师目标
根据
27
位分析师
买入
评级
103.946
目标均价
+1.31%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Incyte Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Incyte Corp简介
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
公司代码INCY
公司Incyte Corp
CEOMeury (Bill)
网址https://www.incyte.com/
相关品种
